Literature DB >> 8719123

Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers.

L H Brauer1, H de Wit.   

Abstract

The role of dopamine in d-amphetamine-induced euphoria has not been systematically examined in normal volunteers. Therefore, we examined the effects of the dopamine antagonist, pimozide, on responses to d-amphetamine in healthy volunteers, using a within-subjects, double-blind design. Ten subjects received single oral doses of d-amphetamine (0, 10, 20 mg) 2 hours following pretreatment with pimozide (0, 1, 2 mg). Subjective, behavioral, and physiological effects were assessed predrug and for 3 hours after d-amphetamine administration. d-Amphetamine alone produced prototypic effects on a variety of measures, including euphoria and drug liking. Pimozide did not produce any effects when administered alone and produced inconsistent effects on responses to d-amphetamine. Although higher doses of pimozide may be needed to antagonize the euphorigenic effects of d-amphetamine, these results raise the possibility that the role of dopamine in the subjective effects of stimulants may be more complex than initially appreciated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8719123     DOI: 10.1016/0006-3223(95)00110-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  34 in total

1.  Influence of aripiprazole pretreatment on the reinforcing effects of methamphetamine in humans.

Authors:  William W Stoops; J Adam Bennett; Joshua A Lile; Rajkumar J Sevak; Craig R Rush
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-08-28       Impact factor: 5.067

2.  Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

Authors:  Jack Bergman; Rebecca A Roof; Cheryse A Furman; Jennie L Conroy; Nancy K Mello; David R Sibley; Phil Skolnick
Journal:  Int J Neuropsychopharmacol       Date:  2012-07-25       Impact factor: 5.176

3.  Individual differences in the reinforcing and subjective effects of d-amphetamine: Dimensions of impulsivity.

Authors:  Arit Harvanko; Catherine Martin; Joshua Lile; Richard Kryscio; Thomas H Kelly
Journal:  Exp Clin Psychopharmacol       Date:  2016-12       Impact factor: 3.157

Review 4.  Novel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.

Authors:  Chris P Bailey; Stephen M Husbands
Journal:  Expert Opin Drug Discov       Date:  2014-09-25       Impact factor: 6.098

5.  In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO.

Authors:  I Boileau; D Payer; B Chugani; D S S Lobo; S Houle; A A Wilson; J Warsh; S J Kish; M Zack
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

Review 6.  Does a shared neurobiology for foods and drugs of abuse contribute to extremes of food ingestion in anorexia and bulimia nervosa?

Authors:  Walter H Kaye; Christina E Wierenga; Ursula F Bailer; Alan N Simmons; Angela Wagner; Amanda Bischoff-Grethe
Journal:  Biol Psychiatry       Date:  2013-02-04       Impact factor: 13.382

7.  Riluzole and D-amphetamine interactions in humans.

Authors:  Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Thomas Kosten
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-05-18       Impact factor: 5.067

Review 8.  Dopamine and reward: the anhedonia hypothesis 30 years on.

Authors:  Roy A Wise
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

9.  Atomoxetine attenuates dextroamphetamine effects in humans.

Authors:  Mehmet Sofuoglu; James Poling; Kevin Hill; Thomas Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

Review 10.  Human drug discrimination: A primer and methodological review.

Authors:  B Levi Bolin; Joseph L Alcorn; Anna R Reynolds; Joshua A Lile; Craig R Rush
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.